PharmStars Ventures adds 11 digital health startups, grows portfolio to 23

PharmStars Ventures said June 23, 2026, that it invested in 11 startups from its Fall 2025 accelerator cohort, lifting its portfolio to 23 companies. The move underscores the fund’s bet that pre-vetted digital health startups can help pharma companies move faster on data, AI, clinical research, and patient engagement.

Why it matters: - PharmStars Ventures is doubling down on digital health startups that are already prepared to work with pharmaceutical companies. - The fund’s model is designed to reduce risk for investors and shorten the path from startup innovation to pharma adoption. - The new investments add momentum to a strategy centered on bridging the gap between startups and pharma buyers.

What happened: - PharmStars Ventures announced 11 new investments from the PharmStars accelerator’s Fall 2025 cohort. - The portfolio now includes 23 companies. - The announcement was made June 23, 2026. - The fund is built around the PharmStars accelerator and focuses on pharma-ready digital health startups.

The details: - The 11 investments target data management, insights, and artificial intelligence. - The companies operate across North America, Europe, and South America. - The portfolio companies work across AI, clinical research, real-world data, wearables, drug discovery, workforce development, and pharma research infrastructure. - PharmStars Ventures says its accelerator pipeline gives it a global source of startups working on pharma’s most pressing operational and clinical challenges. - The accelerator has produced 112 graduates since launching in 2021. - Those graduates have raised more than $1 billion combined. - Early graduates have formed more than 100 partnerships with pharma companies. - The fund works closely with founders during the accelerator’s 10-week Pharma University program on business strategy, positioning, customer engagement, and commercialization. - That longer engagement lets the investment team evaluate teams, technologies, and market opportunities over months rather than weeks. - The fund says the model supports deep due diligence before investing.

Between the lines: - The strategy reflects a thesis that pharma-startup partnerships improve when startups are trained to speak the language of pharmaceutical buyers. - The portfolio mix suggests PharmStars Ventures is spreading risk across stage, geography, and technology rather than backing a single category. - The fund’s close ties to pharma executives and subject-matter experts likely help it spot commercial needs earlier than generalist investors. - Naomi Fried, PhD, said the company’s relationships with leading pharmaceutical companies provide real-time insight into industry challenges and priorities. - Shrawan Patel, MD, said the accelerator-based model allows the fund to identify, vet, and de-risk companies before investing.

What's next: - PharmStars Ventures expects to invest in future accelerator cohorts as it expands its portfolio of pharma-ready digital health companies. - PharmStars’ Fall 2026 accelerator is accepting applications through July 12, 2026. - The next cohort will focus on Digital Innovations in Immunology. - PharmStars Ventures’ website includes more information.